Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26041986
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Front+Neurosci
2015 ; 9
(ä): 182
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Therapeutic benefits of nanoparticles in stroke
#MMPMID26041986
Panagiotou S
; Saha S
Front Neurosci
2015[]; 9
(ä): 182
PMID26041986
show ga
Stroke represents one of the major causes of death and disability worldwide, for
which no effective treatments are available. The thrombolytic drug alteplase
(tissue plasminogen activator or tPA) is the only treatment for acute ischemic
stroke but its use is limited by several factors including short therapeutic
window, selective efficacy, and subsequent haemorrhagic complications. Numerous
preclinical studies have reported very promising results using neuroprotective
agents but they have failed at clinical trials because of either safety issues or
lack of efficacy. The delivery of many potentially therapeutic neuroprotectants
and diagnostic compounds to the brain is restricted by the blood-brain barrier
(BBB). Nanoparticles (NPs), which can readily cross the BBB without compromising
its integrity, have immense applications in the treatment of ischemic stroke. In
this review, potential uses of NPs will be summarized for the treatment of
ischemic stroke. Additionally, an overview of targeted NPs will be provided,
which could be used in the diagnosis of stroke. Finally, the potential
limitations of using NPs in medical applications will be mentioned. Since the use
of NPs in stroke therapy is now emerging and is still in development, this review
is far from comprehensive or conclusive. Instead, examples of NPs and their
current use will be provided, as well as the potentials of NPs in an effort to
meet the high demand of new therapies in stroke.
free
free
free
